The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
Abstract
The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-positive (ER+) breast cancer. Here, we describe the design, synthesis, and extensive structure–activity relationship (SAR) studies of small-molecule ERα degraders based on the proteolysis targeting chimeras (PROTAC) concept. Our efforts have resulted in the discovery of highly potent and effective PROTAC ER degraders, as exemplified by ERD-308 ( 32 ). ERD-308 achieves DC 50 (concentration causing 50% of protein degradation) values of 0.17 and 0.43 nM in MCF-7 and T47D ER+ breast cancer cell lines, respectively, and induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines. Significantly, ERD-308 induces more complete ER degradation than fulvestrant, the only approved selective ER degrader (SERD), and is more effective in inhibition of cell proliferation than fulvestrant in MCF-7 cells. Further optimization of ERD-308 may lead to a new therapy for advanced ER+ breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618
Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569
Stols, L., Gu, M., Dieckman, L., Raffen, R., Collart, F. R., & Donnelly, M. I. (2002) · Protein Expression and Purification · doi:10.1006/prep.2001.1603 · Cited by 526
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
Osborne, C. K., Wakeling, A., & Nicholson, R. I. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601629 · Cited by 414
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Cromm, P. M., & Crews, C. M. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 412
Galdeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Van Molle, I., Birced, I., Hewitt, S., Dias, D. M., & Ciulli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011258 · Cited by 399
Recent Advances in the Treatment of Breast Cancer
Tong, C. W. S., Wu, M., Cho, W. C. S., & To, K. K. W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00227 · Cited by 399
Zhou, B., Hu, J., Xu, F., Chen, Z., Bai, L., Fernandez-Salas, E., Lin, M., Liu, L., Yang, C.-Y., Zhao, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01816 · Cited by 358
Self-citationLu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.063 · Cited by 310
Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206231 · Cited by 302
Sun, Y., Zhao, X., Ding, N., Gao, H., Wu, Y., Yang, Y., Zhao, M., Hwang, J., Song, Y., Liu, W., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0055-1 · Cited by 295
Incidence of Breast Cancer in the United States: Current and Future Trends
Anderson, W. F., Katki, H. A., & Rosenberg, P. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr257 · Cited by 285
Small-Molecule Modulation of Protein Homeostasis
Burslem, G. M., & Crews, C. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00077 · Cited by 283
Qin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281
Self-citationSchiedel, M., Herp, D., Hammelmann, S., Swyter, S., Lehotzky, A., Robaa, D., Oláh, J., Ovádi, J., Sippl, W., & Jung, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01872 · Cited by 263
Crew, A. P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y. V., Hamman, B. D., Morgan, A., Ferraro, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00635 · Cited by 257
Development of subtype-selective oestrogen receptor-based therapeutics
Nilsson, S., Koehler, K. F., & Gustafsson, J.-Å. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3551 · Cited by 249
Ohoka, N., Okuhira, K., Ito, M., Nagai, K., Shibata, N., Hattori, T., Ujikawa, O., Shimokawa, K., Sano, O., Koyama, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.768853 · Cited by 240
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Zhang, C., Han, X.-R., Yang, X., Jiang, B., Liu, J., Xiong, Y., & Jin, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.071 · Cited by 226
Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy
Ottis, P., & Crews, C. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01068 · Cited by 220
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
Robb, C. M., Contreras, J. I., Kour, S., Taylor, M. A., Abid, M., Sonawane, Y. A., Zahid, M., Murry, D. J., Natarajan, A., & Rana, S. (2017) · Chemical Communications · doi:10.1039/c7cc03879h · Cited by 211
Osteoporosis – a current view of pharmacological prevention and treatment
Crockett, J., & Das (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s31504 · Cited by 206
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
Rodriguez-Gonzalez, A., Cyrus, K., Salcius, M., Kim, K., Crews, C. M., Deshaies, R. J., & Sakamoto, K. M. (2008) · Oncogene · doi:10.1038/onc.2008.320 · Cited by 206
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Bai, L., Zhou, B., Yang, C.-Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2622 · Cited by 199
Self-citationDevelopment of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190
McDonnell, D. P., Wardell, S. E., & Norris, J. D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00760 · Cited by 178
Marsaud, V., Gougèlet, A., Maillard, S., & Renoir, J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0269 · Cited by 177
Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation
Ottis, P., Toure, M., Cromm, P. M., Ko, E., Gustafson, J. L., & Crews, C. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00485 · Cited by 176
Weir, H. M., Bradbury, R. H., Lawson, M., Rabow, A. A., Buttar, D., Callis, R. J., Curwen, J. O., de Almeida, C., Ballard, P., Hulse, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2357 · Cited by 175
Fulvestrant: pharmacokinetics and pharmacology
Robertson, J. F. R., & Harrison, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601630 · Cited by 166
Soares, P., Gadd, M. S., Frost, J., Galdeano, C., Ellis, L., Epemolu, O., Rocha, S., Read, K. D., & Ciulli, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00675 · Cited by 165
Martin, L., Ribas, R., Simigdala, N., Schuster, E. F., Pancholi, S., Tenev, T., Gellert, P., Buluwela, L., Harrod, A., Thornhill, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01864-y · Cited by 164
Bihani, T., Patel, H. K., Arlt, H., Tao, N., Jiang, H., Brown, J. L., Purandare, D. M., Hattersley, G., & Garner, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2561 · Cited by 161
Shibata, N., Nagai, K., Morita, Y., Ujikawa, O., Ohoka, N., Hattori, T., Koyama, R., Sano, O., Imaeda, Y., Nara, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00168 · Cited by 148
Wittmann, B. M., Sherk, A. B., & McDonnell, D. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1590 · Cited by 145
The changing role of ER in endocrine resistance
Nardone, A., Angelis, C. D., Trivedi, M. V., Osborne, C. K., & Schiff, R. (2015) · The Breast · doi:10.1016/j.breast.2015.07.015 · Cited by 138
Tria, G. S., Abrams, T. J., Baird, J., Burks, H. E., Firestone, B., Gaither, L. A., Hamann, L. G., He, G., Kirby, C. A., Kim, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01682 · Cited by 137
Overcoming Endocrine Resistance in Hormone Receptor–Positive Breast Cancer
Al-Fakeeh, A., & Brezden‐Masley, C. (2018) · Current Oncology · doi:10.3747/co.25.3752 · Cited by 136
The History and Mechanism of Action of Fulvestrant
Carlson, R. W. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.s.008 · Cited by 133
Joseph, J. D., Darimont, B. D., Zhou, W. J., Arrazate, A., Young, A. E., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., et al. (2016) · eLife · doi:10.7554/elife.15828 · Cited by 132
Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor α
Jiang, Y., Deng, Q. W., Zhao, H., Xie, M., Chen, L., Yin, F., Qin, X., Zheng, W., Zhao, Y. J., & Li, Z. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00985 · Cited by 129
Ohoka, N., Morita, Y., Nagai, K., Shimokawa, K., Ujikawa, O., Fujimori, I., Ito, M., Hayase, Y., Okuhira, K., Shibata, N., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001091 · Cited by 111
On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry
Long, M. J. C., Poganik, J. R., & Aye, Y. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b12608 · Cited by 78
A Good Drug Made Better: The Fulvestrant Dose-Response Story
Robertson, J. F. R., Lindemann, J. P. O., Garnett, S., Anderson, E., Nicholson, R. I., Kuter, I., & Gee, J. M. W. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.06.005 · Cited by 75
Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer
Marchi, T. D., Foekens, J. A., Umar, A., & Martens, J. W. M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.012 · Cited by 73
Seamless Insert-Plasmid Assembly at High Efficiency and Low Cost
Benoit, R., Ostermeier, C., Geiser, M., Li, J. S. Z., Widmer, H., & Auer, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153158 · Cited by 46
Fulvestrant Revisited: Efficacy and Safety of the 500-mg Dose
Howell, A., & Sapunar, F. J. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.02.002 · Cited by 43
Abdel‐Magid, A. F. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00424 · Cited by 12
Cited by
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K.-S., Kaniskan, H. Ü., Xiong, Y., & Jin, J. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00365-x · Cited by 632
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 490
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
Metadata
- Authors
- Hu, J., Hu, B., Wang, M., Xu, F., Miao, B., Yang, C.-Y., Wang, M., Liu, Z., Hayes, D. F., Chinnaswamy, K., Delproposto, J., Stuckey, J., & Wang, S.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-01-18
- Volume
- 62
- Issue
- 3
- Pages
- 1420-1442
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2908747386
- Cited by
- 268
- References
- 59
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.